Floatz logo

LIPEGFILGRASTIM

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

Teva Branded Pharmaceutical Products R&D, Inc.protein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 3BB
Eloxatin
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 2BB
(+)-VINCRISTINE
Universität des Saarlandes
Phase 3B
PEGFILGRASTIM
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3B
Obinutuzumab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B

View all 50 →

Same molecule, other indications

LIPEGFILGRASTIM is also rated in:

lymphomaDormant
CC
Indicative ·
41 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
40 / 100
View asset →
breast cancerDormant
D
Indicative ·
26 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →